Tag: Merkel Cell Carcinoma
Click to read the study in JAMA Dermatology.
Click to read the study in the Journal of the American Academy of Dermatology.
Click to read the study in the Journal of the American Academy of Dermatology.
1. Using immune checkpoint blockade, this phase 2 study showed favourable complete and partial response rates, and increased progression free survival at 6 months, when using programmed cell death-1 (PD-1) blocker pembrolizumab as a first-line therapy for advanced Merkel-cell carcinoma.
2. Responses to pembrolizumab were seen in both positive and...
1. Over the past two decades, the incidence of Merkel Cell Carcinoma (MCC) in the Queensland region has increased by an average of 2.6% annually.
2. Compared to other reports worldwide, MCC occurred at a relatively higher rate in Queensland, a region with a predominantly fair-skinned demographic that is subjected...
Image: CC/Wiki
1. Immunosuppression was associated with a higher likelihood of Merkel Cell Carcinoma (MCC)-specific mortality. Other factors that affected MCC-specific prognosis include tumor site and extent, results of pathologic nodal evaluation, and presence of radiation treatment.
2. Metastatic MCC of unknown primary sites were associated with significantly improved outcomes.
Evidence Rating...